The current understanding on the impact of KRAS on colorectal cancer - 17/06/21

Doi : 10.1016/j.biopha.2021.111717

Mingjing Meng ^a,^{^{1
These authors contributed equally to this work.}}, Keying Zhong ^a,^{^{1
These authors contributed equally to this work.}}, Ting Jiang ^a, Zhongqiu Liu ^a,^b,^⁎ , Hiu Yee Kwan ^c,^⁎ , Tao Su ^a,^b,^⁎
^a Guangdong Key Laboratory for Translational Cancer Research of Chinese Medicine, Joint Laboratory for Translational Cancer Research of Chinese Medicine of the Ministry of Education of the People’s Republic of China, International Institute for Translational Chinese Medicine, School of Pharmaceutical Science, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China
^b Guangdong-Hong Kong-Macau Joint Lab on Chinese Medicine and Immune Disease Research, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China
^c Centre for Cancer and Inflammation Research, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China

^⁎Correspondence to: Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, 510006, China.Guangzhou University of Chinese MedicineGuangzhouGuangdong510006China^⁎⁎Correspondence to: Hong Kong Baptist University, 7 Baptist University Road, Kowloon Tong, Hong Kong, China.Hong Kong Baptist University7 Baptist University RoadKowloon TongHong Kong, China

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

pages	13
Iconographies	3
Vidéos	0
Autres	0

Abstract

KRAS (kirsten rat sarcoma viral oncogene) is a member of the RAS family. KRAS mutations are one of most dominant mutations in colorectal cancer (CRC). The impact of KRAS mutations on the prognosis and survival of CRC patients drives many research studies to explore potential therapeutics or target therapy for the KRAS mutant CRC. This review summarizes the current understanding of the pathological consequences of the KRAS mutations in the development of CRC; and the impact of the mutations on the response and the sensitivity to the current front-line chemotherapy. The current therapeutic strategies for treating KRAS mutant CRC, the difficulties and challenges will also be discussed.

Le texte complet de cet article est disponible en PDF.

Abbreviations : KRAS, CRC, APC, MSI-low, GTP, GAPs, EGFR, Grb2, GEFs, VEGF, TCGA, GAPDH, TTR, SAR, OS, DSS, PDE4, FFPE, HRM, IGF-1R, FDA, HR

Keywords : Colorectal cancer, KRAS, Mutation, Therapy

Plan

Introduction

General physiological functions of KRAS

KRAS gene mutation in CRC

Impact of KRAS mutations on CRC development

Prognostic role of KRAS in colorectal liver metastasis (CRLM)

Prognostic role of KRAS in colorectal lung metastasis

Impact of KRAS mutations on prognosis and survival of CRC patients

KRAS mutations affect the efficacy of the front-line CRC chemotherapy

KRAS mutation is a predictive marker of response to EGFR targeting antibodies in CRC treatment

Interplay of KRAS mutations and primary tumor laterality in colorectal liver metastases

KRAS mutation status influences the choice of the surgical techniques

Current therapeutic strategy for treating KRAS-mutanted CRC

Directly targeting the KRAS mutant

Inhibiting the KRAS-related signaling pathways

Using the synthetic lethality approach

Using the targeted microRNA approach

Targeting the cancer metabolism

Export

Vol 140

Article 111717- août 2021 Retour au numéro

Article précédent

Multiple strategies with the synergistic approach for addressing colorectal cancer
Chenmala Karthika, Balaji Hari, Md. Habibur Rahman, Rokeya Akter, Agnieszka Najda, Ghadeer M. Albadrani, Amany A. Sayed, Muhammad Furqan Akhtar, Mohamed M. Abdel-Daim

| Article suivant

Mechanistic insights and perspectives involved in neuroprotective action of quercetin
Amarjot Kaur Grewal, Thakur Gurjeet Singh, Deepak Sharma, Veerta Sharma, Manjinder Singh, Md. Habibur Rahman, Agnieszka Najda, Magdalena Walasek-Janusz, Mohamed Kamel, Ghadeer M. Albadrani, Muhammad Furqan Akhtar, Ammara Saleem, Mohamed M. Abdel-Daim

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.

Déjà abonné à cette revue ?

connectez-vous ou créez un compte

The current understanding on the impact of KRAS on colorectal cancer - 17/06/21

Abstract

Plan

Export citations

Fichier

Contenu

Accès rapides

Mon compte

Aide & support

Plateformes Elsevier Masson

Déclaration CNIL